Potent anticancer activity against both BRAF-mutant and BRAF wild-type melanoma cell lines using a novel CRM1 nuclear export inhibitor

被引：0
|
作者：
Fragomeni, Roberto A. Salas [1 ]
Chung, Hye-Won [1 ]
Shacham, Sharon [2 ]
Kauffman, Michael [2 ]
Cusack, James C. [1 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Karyopharm Therapeut, Newton, MA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-1914
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1914
引用
收藏
页数：1
相关论文
共 12 条
  • [1] Specific Effect of BRAF-Inhibitors on a BRAF-mutant and a Wild-type Cell Line of Malignant Melanoma
    Steck, M.
    Grabenbauer, M.
    Fuenfle, R.
    Hecht, M.
    Fietkau, R.
    Distel, L., V
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S169 - S170
  • [2] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Wong, Deborah J. L.
    Robert, Lidia
    Atefi, Mohammad S.
    Lassen, Amanda
    Avarappatt, Geetha
    Cerniglia, Michael
    Avramis, Earl
    Tsoi, Jennifer
    Foulad, David
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Samatar, Ahmed
    Lo, Roger S.
    Ribas, Antoni
    MOLECULAR CANCER, 2014, 13
  • [3] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Deborah JL Wong
    Lidia Robert
    Mohammad S Atefi
    Amanda Lassen
    Geetha Avarappatt
    Michael Cerniglia
    Earl Avramis
    Jennifer Tsoi
    David Foulad
    Thomas G Graeber
    Begonya Comin-Anduix
    Ahmed Samatar
    Roger S Lo
    Antoni Ribas
    Molecular Cancer, 13
  • [4] Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Deborah JL Wong
    Lidia Robert
    Mohammad S Atefi
    Amanda Lassen
    Geetha Avarappatt
    Michael Cerniglia
    Earl Avramis
    Jennifer Tsoi
    David Foulad
    Thomas G Graeber
    Begonya Comin-Anduix
    Ahmed Samatar
    Roger S Lo
    Antoni Ribas
    Molecular Cancer, 14
  • [5] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma (vol 13, 194, 2014)
    Wong, Deborah J. L.
    Robert, Lidia
    Atefi, Mohammad S.
    Lassen, Amanda
    Avarappatt, Geetha
    Cerniglia, Michael
    Avramis, Earl
    Tsoi, Jennifer
    Foulad, David
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Samatar, Ahmed
    Lo, Roger S.
    Ribas, Antoni
    MOLECULAR CANCER, 2015, 14
  • [6] cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines
    Journe, F.
    Wiedig, M.
    Morandini, R.
    Sales, F.
    Ghanem, G.
    Awada, A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 83 - 84
  • [7] Functional analysis of gene expression profiling of primary and metastatic melanoma: Possible implications from BRAF mutant and wild-type cell lines
    Essner, Richard
    Gong, Ke Wei
    Chmielowski, Bartosz
    Finn, Richard
    Tap, William D.
    Slamon, Dennis
    CANCER RESEARCH, 2012, 72
  • [8] AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes
    Wang, Hongbin
    Quan, Haitian
    Lou, Liguang
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 489 (01) : 14 - 20
  • [9] Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma
    Kong, Sun-Young
    Landesman, Yosef
    Jakubikova, Jana
    Sellitto, Michael A.
    Cagnetta, Antonia
    Cea, Michele
    Chen, Michelle C.
    Cottini, Francesca
    McMillin, Douglas W.
    Acharya, Chirag
    Senapedis, William
    Shacham, Sharon
    Kauffman, Michael
    McCauley, Dilara
    Saint-Martin, Jean-Richard
    Munshi, Nikhil C.
    Richardson, Paul G.
    Anderson, Kenneth C.
    Tai, Yu-Tzu
    BLOOD, 2011, 118 (21) : 1256 - 1257
  • [10] Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
    Breit, Megan N.
    Kisseberth, William C.
    Bear, Misty D.
    Landesman, Yosef
    Kashyap, Trinayan
    McCauley, Dilara
    Kauffman, Michael G.
    Shacham, Sharon
    London, Cheryl A.
    BMC VETERINARY RESEARCH, 2014, 10
12